U.S. regulatory status
Selank
Also known as Selank acetate · TP-7
Is Selank legal right now?
Selank sits in a regulatory gray area in the United States. It was removed from Category 2 of the interim 503A bulks list in 2024 after its nomination was withdrawn — but removal from Category 2 does not place a substance on the 503A list or into Category 1, and the FDA has not stated it will exercise enforcement discretion for it. Legal analyses describe such peptides as being in limbo pending advisory committee review. Selank is not among the seven peptides scheduled for the July 2026 PCAC meeting and has no set decision date, so its compounding status is unresolved.
In limbo: Nominated or removed from a restricted list but NOT approved — the headline implies a change, but the legal reality did not move.
Current status held since Sep 27, 2024 · last verified Jul 7, 2026 (ET)
Where it sits in the process
- Nominated(stalled here — not advancing)
- Under review(not reached)
- Rulemaking(not reached)
- Compounding-legal(not reached)
Not on a path to the 503A list right now. The process stalled or reversed at this stage — read the status above. Sitting at an earlier step is not a sign it will advance.
What changed last
Removed from Category 2 after its nomination was withdrawn — not placed on the 503A list, so compounding remained unauthorized.
Status elsewhere
| Jurisdiction | Status | Note |
|---|---|---|
| United States (FDA) | In limbo | Removed from Category 2 (~Sept 2024); never in Category 1; not on the 503A list; no scheduled PCAC review. |
| Australia (TGA) | Unscheduled | Not individually named or scheduled in the Poisons Standard. |
| Sport / anti-doping (WADA) | Restricted | Falls under S0 (non-approved substances); prohibited at all times for tested athletes. |
Sources & transparency
Sources for this entry
- FDA — 503A bulk drug substances: Category 1 & Category 2 lists FDA · primarySelank is not on the 503A list and was never in Category 1; the FDA 503A categories define compounding eligibility.
- Orrick — FDA removal of peptides from Category 2; PCAC meetings analysisRemoval from Category 2 does not, by itself, place substances on the 503A list.
- Pharmacy Times — the peptide reclassification, explained analysisRemoval / Category 1 is not FDA approval; the mechanics are still working through the system.
- FDA Law Blog — FDA's Pep(tide) Rally (Hyman, Phelps & McNamara) analysisSelank is not on the July 23–24, 2026 PCAC agenda.
- Last verified by a human
- Jul 7, 2026 (ET) · how we verify
- Who runs this
- Peptlas Research Team — independent. About us.
- What we sell
- Nothing. No products, no affiliates, no sponsored placements.
- Confidence
- medium — some facts here rest on secondary reporting. Always confirm against the primary source before you rely on it.
This page reports publicly available regulatory status for information only. It isnot medical or legal advice and makes no health claim. See ourfull disclaimer.
Get alerted when Selank's status changes
We'll email you only when this entry's official status moves — and never anything else.